AXCES Research Group, LLC. | El Paso, TX

Research site

(Unclaimed)

Location

1800 North Mesa Street Suite 100, El Paso, Texas, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Bictegravir

Islatravir

GS-1219

Tenofovir Alafenamide

GS-1720

GS-4182

GS-3242

GS-2872

GS-5423

Parent organization

This site is a part of AXCES Research Group, LLC.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV-1 Infection

Drug: Lenacapavir Injection

Drug: Lenacapavir Tablet

Study of GS-3242 in Participants With HIV-1; Substudy-05

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that...

Enrolling

HIV-1-infection

Drug: Standard of Care

Drug: GS-3242

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting

HIV-1-Infection

Drug: Lepetegravir

Drug: Lepetegravir/Lenacapavir pacfosacil FDC

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: PTM ISL/LEN

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting

HIV-1-Infection

Drug: Antiretroviral Combinations

Drug: ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: Placebo to match B/F/TAF

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms